Surgical Treatment of Ischemic Heart Disease: Complete 2026 Doctor’s Guide

By Dr. Sagar Rajkuwar, ENT Specialist, Nashik, Maharashtra, India
🌐 www.entspecialistinnashik.com

Short answer: The surgical treatment of ischemic heart disease primarily consists of coronary artery bypass grafting (CABG), in which healthy blood vessels — the left internal mammary artery (LIMA), right internal mammary artery (RIMA), radial artery, or great saphenous vein — are used to bypass severely narrowed coronary arteries. Modern options also include off-pump CABG (OPCAB), minimally invasive direct coronary artery bypass (MIDCAB), robotic and hybrid revascularisation, transmyocardial laser revascularisation (TMLR), and in advanced ischaemic cardiomyopathy — left ventricular assist devices (LVAD) and cardiac transplantation. If you are reading about the surgical treatment of ischemic heart disease, this 2026 ENT-authored guide — built on WHO, CDC, NHS, AHA/ACC/SCAI 2021 Revascularisation Guideline, and ESC 2024 Chronic Coronary Syndromes — explains every option in depth.

Table of Contents

1. Introduction
2. Why Surgery for Ischemic Heart Disease
3. Indications for CABG
4. CABG — The Classical Operation
5. Types of Grafts Used
6. On-Pump vs Off-Pump CABG
7. Minimally Invasive CABG (MIDCAB)
8. Robotic & Totally Endoscopic CABG
9. Hybrid Revascularisation (CABG + PCI)
10. Transmyocardial Laser Revascularisation (TMLR)
11. Surgery for Mechanical Complications of MI
12. Advanced Heart Failure Surgery — LVAD & Transplant
13. Risks & Complications
14. Recovery, ICU & Hospital Stay
15. Life After Surgery
16. Outcomes & Long-Term Survival
17. Latest 2024–2026 Advances
18. External Video Resource
19. FAQs
20. Conclusion
21. References

1. Introduction

While percutaneous coronary intervention (PCI) is the most common revascularisation worldwide, surgery remains the gold standard for complex multivessel and left-main disease. The surgical treatment of ischemic heart disease has evolved from large-incision bypass surgery in the 1960s to today’s robotic, hybrid and arterial-only revascularisation.

2. Why Surgery for Ischemic Heart Disease

• Better long-term survival in multivessel disease, especially with diabetes (FREEDOM trial)
• Durable arterial grafts last 15–20+ years
• Reduces repeat revascularisation
• Addresses heart-failure complications of chronic ischaemia
• Treats mechanical post-MI complications

In short, the surgical treatment of ischemic heart disease is reserved for patients where PCI would be sub-optimal, when complex anatomy exists, or when complications demand open repair.

3. Indications for CABG

Current ACC/AHA/SCAI 2021 and ESC 2024 guidelines recommend CABG for:

• Left main coronary artery stenosis ≥50% (especially with high SYNTAX score)
• Three-vessel CAD, especially with impaired LV function (EF <35%)
• Multivessel CAD with diabetes mellitus (FREEDOM)
• Proximal LAD disease plus other vessels
• Failed PCI with persistent ischaemia
• CABG combined with valve surgery
• Mechanical complications of MI (VSR, papillary muscle rupture)
• Patients unsuitable for PCI due to anatomy, calcification, chronic total occlusions

4. CABG — The Classical Operation

4.1 Overview

Coronary artery bypass grafting (CABG), pronounced “cabbage”, creates new conduits around blocked coronary arteries so that oxygenated blood reaches the myocardium beyond the obstruction.

4.2 Standard steps

1. General anaesthesia + endotracheal intubation
2. Median sternotomy (standard) or minimally invasive approach
3. Harvest of conduits (LIMA, RIMA, radial, saphenous vein)
4. Cannulation of aorta & right atrium for cardiopulmonary bypass
5. Cardioplegia to arrest the heart (on-pump) or stabilisers (off-pump)
6. Distal anastomoses to coronaries beyond the stenosis
7. Proximal anastomoses to the aorta
8. Wean from bypass; reverse heparin with protamine
9. Sternal closure

These steps are the foundation of the surgical treatment of ischemic heart disease.

5. Types of Grafts Used

5.1 Arterial grafts (preferred)

• Left internal mammary artery (LIMA) — gold-standard graft to LAD; 20-year patency >90%
• Right internal mammary artery (RIMA) — second-best arterial conduit; useful in young patients, non-diabetic
• Radial artery — excellent patency, requires calcium-channel blocker post-op
• Right gastroepiploic artery — rarely used today

5.2 Venous graft

• Great saphenous vein — easy harvest, large diameter; 10-year patency ~50%
• Endoscopic vein harvest (EVH) reduces wound complications

5.3 Trend

“Total arterial revascularisation” (bilateral IMA + radial) is preferred in younger patients due to superior long-term patency.

6. On-Pump vs Off-Pump CABG

6.1 On-Pump CABG

• Standard worldwide
• Heart arrested with cardioplegia
• Cardiopulmonary bypass machine maintains perfusion
• Technically easier, bloodless field

6.2 Off-Pump CABG (OPCAB) / Beating-Heart Surgery

• Heart continues to beat; stabiliser devices used
• Avoids CPB-related inflammation, renal stress, cognitive dysfunction
• Preferred in elderly, atheromatous aorta, renal impairment
• Requires experienced surgeon; graft patency slightly lower in some trials (ROOBY, CORONARY)

7. Minimally Invasive CABG (MIDCAB)

• Small left-anterior thoracotomy, no sternotomy
• LIMA → LAD bypass (single-vessel disease)
• Faster recovery, less pain, lower infection risk
• Often part of hybrid revascularisation

8. Robotic & Totally Endoscopic CABG

• da Vinci surgical robot for LIMA harvest and anastomoses
• Totally endoscopic coronary artery bypass (TECAB) — no incision over sternum
• Shorter hospital stay, excellent cosmetic result
• Available in selected tertiary centres

9. Hybrid Revascularisation (CABG + PCI)

• Robotic/MIDCAB LIMA to LAD + PCI stenting of other vessels
• Combines durability of LIMA–LAD graft with less invasiveness of PCI elsewhere
• Decision taken by the Heart Team

10. Transmyocardial Laser Revascularisation (TMLR)

• Creation of tiny channels in ischaemic myocardium with CO₂/holmium laser
• Promotes angiogenesis
• Used in refractory angina not amenable to CABG or PCI
• Can be combined with CABG for hybrid relief

11. Surgery for Mechanical Complications of MI

• Ventricular septal rupture (VSR) — surgical patch repair
• Papillary muscle rupture — mitral valve replacement/repair
• Left ventricular aneurysm — Dor procedure (surgical ventricular restoration)
• Free wall rupture — emergency pericardial patch, usually under VA-ECMO
• Post-MI pseudoaneurysm — surgical repair

12. Advanced Heart Failure Surgery — LVAD & Transplant

• Left ventricular assist device (LVAD) — HeartMate 3 (centrifugal, magnetically levitated); bridge-to-transplant or destination therapy
• Cardiac transplantation — definitive for end-stage ischaemic cardiomyopathy; 10-year survival ~55%
• Total artificial heart — rare, as a bridge
• Extracorporeal membrane oxygenation (ECMO) — in cardiogenic shock

These advanced options sit at the far end of the surgical treatment of ischemic heart disease spectrum.

13. Risks & Complications

• Overall 30-day mortality ~1–3% in elective CABG; higher in emergency
• Bleeding, re-exploration
• Perioperative MI
• Stroke (1–2%)
• Atrial fibrillation (20–40%)
• Renal dysfunction
• Sternal wound infection, mediastinitis
• Deep vein thrombosis, pulmonary embolism
• Cognitive dysfunction, delirium
• Graft occlusion

14. Recovery, ICU & Hospital Stay

• ICU stay 1–2 days
• Total hospital stay 5–7 days
• Extubation often within 4–8 hours
• Early ambulation on day 1
• Chest tubes removed on day 2–3
• Sternal precautions for 6–8 weeks
• No driving for 4–6 weeks
• Cardiac rehabilitation starts at week 4–6

15. Life After Surgery

• Guideline-directed medical therapy continues lifelong
• Dual antiplatelet therapy typically 1 year, then aspirin alone
• High-intensity statin to LDL target
• Beta-blocker, ACE-I/ARB if indicated
• Mediterranean/DASH diet, exercise, no tobacco
• Weight & waist control, sleep hygiene, stress reduction
• Annual flu, pneumococcal, COVID-19 vaccinations

16. Outcomes & Long-Term Survival

• 5-year survival ~90%, 10-year ~75% in uncomplicated elective CABG
• LIMA–LAD graft patency >90% at 20 years
• Diabetic patients with multivessel disease: CABG superior to PCI for mortality (FREEDOM)
• Quality-of-life improvement is dramatic in most patients

17. Latest 2024–2026 Advances

• Expanded robotic CABG programmes in India and Europe
• No-touch saphenous vein harvesting (improved long-term patency)
• Composite & sequential arterial grafting
• HeartMate 3 destination therapy — 5-year survival now ~58%
• Xenotransplantation (porcine heart) — first human cases 2022–2024
• AI-guided surgical planning & 3D printing of anatomy
• Enhanced recovery after cardiac surgery (ERACS) protocols

18. External Video Resource

Watch a visual explainer on the surgical treatment of ischemic heart disease:

YouTube: CABG Surgery Explained – BHF / AHA / Cleveland Clinic

19. FAQs

Q1. How long does CABG surgery take?

3–6 hours depending on number of grafts and complexity.

Q2. Will I be awake during surgery?

No — general anaesthesia; you’ll be fully asleep.

Q3. How long before I can drive?

4–6 weeks after sternotomy; sooner after MIDCAB.

Q4. Will the grafts block again?

LIMA grafts have excellent long-term patency; venous grafts have ~50% occlusion at 10 years without strict risk-factor control.

Q5. Can CABG be redone?

Yes — redo CABG is technically more difficult but feasible in selected patients; PCI is often preferred.

Q6. Is CABG painful?

Moderate pain for the first week, controlled with multimodal analgesia; sternal pain subsides over 6–8 weeks.

Q7. Can I live a normal life after CABG?

Yes — most patients return to work, exercise, drive, travel, and enjoy an improved quality of life.

Q8. Is bypass better than stent?

For left-main disease with high SYNTAX, 3-vessel disease with diabetes, or impaired LV function — yes. For single-vessel or non-complex multivessel disease — PCI is comparable.

20. Conclusion

The surgical treatment of ischemic heart disease remains a cornerstone of modern cardiology. CABG — especially with arterial grafts — offers durable, long-term protection against future ischaemic events in complex anatomy, diabetes, and reduced LV function. Combined with lifelong guideline-directed medical therapy, lifestyle modification, and cardiac rehabilitation, surgery can transform a life-limiting disease into a well-controlled chronic condition.

21. References

1. Lawton JS, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularisation.
2. Vrints C, et al. 2024 ESC Guidelines on Chronic Coronary Syndromes.
3. Farkouh ME, et al. FREEDOM trial. NEJM 2012; 7-year follow-up 2019.
4. Stone GW, et al. EXCEL trial. NEJM 2016, 2019.
5. Serruys PW, et al. SYNTAX trial. NEJM 2009; long-term follow-up 2019.
6. Mehra MR, et al. HeartMate 3 MOMENTUM trial. NEJM 2017; 5-year follow-up 2022.
7. WHO Cardiovascular Diseases Fact Sheet 2024.

📞 ENT Consultation & Surgery

Dr. Sagar Rajkuwar (MS-ENT)
Prabha ENT Clinic, Ambad, Nashik
📱 7387590194 | 9892596635
🌐 www.entspecialistinnashik.com

Medical Disclaimer

Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Audiogram results should be interpreted by a qualified audiologist or ENT specialist. If you have sudden hearing loss, severe dizziness, ear discharge, or other concerning symptoms, seek medical evaluation promptly. Always consult a qualified cardiothoracic surgeon or cardiologist for surgical management of ischemic heart disease.